{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T22:32:29Z","timestamp":1780698749488,"version":"3.54.1"},"reference-count":47,"publisher":"American Society for Microbiology","issue":"11","license":[{"start":{"date-parts":[[2006,11,1]],"date-time":"2006-11-01T00:00:00Z","timestamp":1162339200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2006,11]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            Arbekacin, a derivative of dibekacin, is an aminoglycoside developed and widely used in Japan for the treatment of patients infected with methicillin-resistant\n            <jats:italic>Staphylococcus aureus<\/jats:italic>\n            (MRSA). The population pharmacokinetics of arbekacin was investigated in the Japanese, using 353 patients infected with MRSA and 50 healthy or renally impaired volunteers. The age of the study population ranged from 8 to 95 years, and weight ranged from 10.8 to 107 kg. In total, 1,581 serum arbekacin concentrations were measured (primarily from routine patient care) and used to perform the present pharmacokinetic analysis. Drug concentration-time data were well described by a two-compartment open model. Factors influencing arbekacin pharmacokinetics were investigated using a nonlinear mixed-effect model analysis. The best-developed model showed that drug clearance (CL) was related to creatinine clearance (CL\n            <jats:sub>CR<\/jats:sub>\n            ), age, and body weight (WT), as expressed by CL (liter\/h) = 0.0319CL\n            <jats:sub>CR<\/jats:sub>\n            + (26.5\/age) (CL\n            <jats:sub>CR<\/jats:sub>\n            &lt; 80 ml\/min) and CL (liter\/h) = 0.0130 CL\n            <jats:sub>CR<\/jats:sub>\n            + 0.0342WT + (26.5\/age) (CL\n            <jats:sub>CR<\/jats:sub>\n            \u2265 80 ml\/min). The volume of distribution for the central and peripheral compartments was different in healthy subjects and infected patients, and this difference was more pronounced among disease types. The elderly subjects (aged 80 years or over) exhibited, on average, a 19% greater volume for the central compartment. The volumes for the peripheral compartment were 50.6 liters in patients with pneumonia and 24.3 liters in patients with sepsis. The population pharmacokinetic parameters of arbekacin obtained here are useful for optimal use of this aminoglycoside in the treatment of MRSA-infected patients.\n          <\/jats:p>","DOI":"10.1128\/aac.00420-05","type":"journal-article","created":{"date-parts":[[2006,10,25]],"date-time":"2006-10-25T20:58:50Z","timestamp":1161809930000},"page":"3754-3762","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":29,"title":["Population Pharmacokinetics of Arbekacin in Patients Infected with Methicillin-Resistant\n            <i>Staphylococcus aureus<\/i>"],"prefix":"10.1128","volume":"50","author":[{"given":"Yusuke","family":"Tanigawara","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Keio University Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reiko","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Keio University Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunihiko","family":"Morita","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Keio University Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuo","family":"Kaku","sequence":"additional","affiliation":[{"name":"Division of Molecular Diagnostics, Department of Clinical Medicine, Tohoku University, Graduate School of Medicine, Sendai, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Aikawa","sequence":"additional","affiliation":[{"name":"Department of Emergency and Critical Care Medicine, Keio University Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kihachiro","family":"Shimizu","sequence":"additional","affiliation":[{"name":"The Kitasato Institute, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","first-page":"640","volume":"47","year":"1994","unstructured":"Aoki, Y. 1994. Bactericidal activity of arbekacin against methicillin-resistant Staphylococcus aureus. Comparison with that of vancomycin. Jpn. J. Antibiot.47:640-646.","journal-title":"Jpn. J. Antibiot."},{"key":"e_1_3_2_3_2","first-page":"697","volume":"35","year":"1989","unstructured":"Arakawa, S., H. Maeda, A. Fujii, S. Kamidono, K. Hamada, S. Miyazaki, and S. Hara. 1989. Clinical study of aminoglycoside on renal dysfunction. Pharmacokinetics of arbekacin and its elimination effects by hemodialysis and adsorption with charcoal. Acta Urol. Jpn.35:697-704.","journal-title":"Acta Urol. Jpn."},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1159\/000180580"},{"key":"e_1_3_2_5_2","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/S0009-9236(97)90117-X","volume":"62","year":"1997","unstructured":"de Hoog, M., R. C. Schoemaker, J. W. Mouton, and J. N. van den Anker. 1997. Tobramycin population pharmacokinetics in neonates. Clin. Pharmacol. Ther.62:392-399.","journal-title":"Clin. Pharmacol. Ther."},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1997.tb04326.x"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.31.4.575"},{"key":"e_1_3_2_8_2","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1093\/jac\/41.4.495","volume":"41","year":"1998","unstructured":"Fujimura, S., Y. Tokue, H. Takahashi, T. Nukiwa, K. Hisamichi, T. Mikami, and A. Watanabe. 1998. A newly recognized acetylated metabolite of arbekacin in arbekacin-resistant strains of methicillin-resistant Staphylococcus aureus. J. Antimicrob. Chemother.41:495-497.","journal-title":"J. Antimicrob. Chemother."},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.40.5.1153"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.8.4.434"},{"key":"e_1_3_2_11_2","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1093\/jac\/35.6.865","volume":"35","year":"1995","unstructured":"Hamilton-Miller, J. M. T., and S. Shah. 1995. Activity of the semi-synthetic kanamycin B derivative, arbekacin against methicillin-resistant Staphylococcus aureus. J. Antimicrob. Chemother.35:865-868.","journal-title":"J. Antimicrob. Chemother."},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(97)07324-8"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.3.623"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.4.1159-1167.2004"},{"key":"e_1_3_2_15_2","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1097\/00007691-200310000-00012","volume":"25","year":"2003","unstructured":"Kirkpatrick, C. M. J., S. B. Duffull, E. J. Begg, and C. Frampton. 2003. The use of a change in gentamicin clearance as an early predictor of gentamicin-induced nephrotoxicity. Ther. Drug Monit.25:623-630.","journal-title":"Ther. Drug Monit."},{"key":"e_1_3_2_16_2","first-page":"82","volume":"34","year":"1986","unstructured":"Komiya, I., N. Mitomi, and M. Nishio. 1986. Assay method of HBK in biological fluids. II. High-performance liquid chromatographic assay method. Chemotherapy34:82-86.","journal-title":"Chemotherapy"},{"key":"e_1_3_2_17_2","doi-asserted-by":"crossref","first-page":"412","DOI":"10.7164\/antibiotics.26.412","volume":"26","year":"1973","unstructured":"Kondo, S., K. Iinuma, H. Yamamoto, K. Maeda, and H. Umezawa. 1973. Syntheses of 1-N-{(S)-4-amino-2-hydroxybutyryl}-kanamycin B and -3\u2032, 4\u2032-dideoxykanamycin B active against kanamycin-resistant bacteria. J. Antibiot.26:412-415.","journal-title":"J. Antibiot."},{"key":"e_1_3_2_18_2","first-page":"200","volume":"42","year":"1989","unstructured":"Kumon, H., A. Mizuno, Y. Nasu, M. Tsugawa, M. Kishi, and H. Ohmori. 1989. Pharmacokinetics of arbekacin in healthy volunteers and patients with renal insufficiency. Jpn. J. Antibiot.42:200-207.","journal-title":"Jpn. J. Antibiot."},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002280050666"},{"key":"e_1_3_2_20_2","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1365-2125.2005.02260.x","volume":"59","year":"2005","unstructured":"Lingvall, M., D. Reith, and R. Broadbent. 2005. The effect of sepsis upon gentamicin pharmacokinetics in neonates. Br. J. Clin. Pharmacol.59:54-61.","journal-title":"Br. J. Clin. Pharmacol."},{"key":"e_1_3_2_21_2","first-page":"784","volume":"10","year":"1991","unstructured":"Longley, J. M., D. G. Pittman, and F. D. Newby. 1991. Altered aminoglycoside volume of distribution in patients with acquired immunodeficiency syndrome. Clin. Pharm.10:784-786.","journal-title":"Clin. Pharm."},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1177\/0310057X9302100206"},{"key":"e_1_3_2_23_2","first-page":"523","volume":"41","year":"1988","unstructured":"Matsuhashi, Y., and H. Yamamoto. 1988. The enzymatic mechanisms of resistance to aminoglycoside antibiotics in methicillin-cephem-resistant Staphylococcus aureus. Jpn. J. Antibiot.41:523-529.","journal-title":"Jpn. J. Antibiot."},{"key":"e_1_3_2_24_2","first-page":"309","volume":"15","year":"1999","unstructured":"Matsuno, T., N. Suzuki, S. Kawai, S. Han, Y. Mizutani, H. Fujii, and M. Takahashi. 1999. A method of effective administration for arbekacin (ABK)-2. Jpn. J. Ther. Drug Monit.15:309-313.","journal-title":"Jpn. J. Ther. Drug Monit."},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.12.2597"},{"key":"e_1_3_2_26_2","first-page":"357","volume":"40","year":"1987","unstructured":"Mitomi, N., T. Matsumoto, M. Fujigaki, I. Komiya, and F. Kai. 1987. Absorption, distribution, and excretion of arbekacin after intravenous and intramuscular administration in rats. Jpn. J. Antibiot.40:357-364.","journal-title":"Jpn. J. Antibiot."},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/155.1.93"},{"key":"e_1_3_2_28_2","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/0002-9343(84)90358-9","volume":"77","year":"1984","unstructured":"Moore, R. D., C. R. Smith, and P. S. Lietman. 1984. Association of aminoglycoside plasma levels with therapeutic outcome in gram-negative pneumonia. Am. J. Med.77:657-662.","journal-title":"Am. J. Med."},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.3.650"},{"key":"e_1_3_2_30_2","first-page":"131","volume":"12","year":"1993","unstructured":"Oparaoji, E. C., E. E. Cornwell III, E. Hekmat, R. Lun Cheong, J. S. Adir, and S. Siram. 1993. Aminoglycoside volume of distribution in postoperative patients with septic shock. Clin. Pharm.12:131-134.","journal-title":"Clin. Pharm."},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0169-2607(98)00098-4"},{"key":"e_1_3_2_32_2","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1097\/00007691-198503000-00003","volume":"7","year":"1985","unstructured":"Ristuccia, A. M., and B. A. Cunha. 1985. An overview of amikacin. Ther. Drug Monit.7:12-25.","journal-title":"Ther. Drug Monit."},{"key":"e_1_3_2_33_2","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/jac\/44.2.235","volume":"44","year":"1999","unstructured":"Romano, S., M. M. Fdez de Gatta, M. V. Calvo, D. Caballero, A. Dominguez-Gil, and J. M. Lanao. 1999. Population pharmacokinetics of amikacin in patients with haematological malignancies. J. Antimicrob. Chemother.44:235-242.","journal-title":"J. Antimicrob. Chemother."},{"key":"e_1_3_2_34_2","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1046\/j.1365-2125.1998.00779.x","volume":"46","year":"1998","unstructured":"Rosario, M. C., A. H. Thomson, D. I. Jodrell, C. A. Sharp, and H. L. Elliott. 1998. Population pharmacokinetics of gentamicin in patients with cancer. Br. J. Clin. Pharmacol.46:229-236.","journal-title":"Br. J. Clin. Pharmacol."},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.7.1549"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00480-05"},{"key":"e_1_3_2_37_2","first-page":"47","volume":"17","year":"2000","unstructured":"Shibasaki, S., N. Mitomi, T. Matsumoto, N. Morishita, T. Matsuno, H. Fujii, Y. Tanigawara, and K. Okumura. 2000. Population pharmacokinetic analysis of arbekacin in Japanese. Jpn. J. Ther. Drug Monit.17:47-53.","journal-title":"Jpn. J. Ther. Drug Monit."},{"key":"e_1_3_2_38_2","first-page":"72","volume":"34","year":"1986","unstructured":"Shinkai, S., N. Ishiwatari, and M. Fujita. 1986. Assay method of HBK in biological fluids. I. Microbiological assay method. Chemotherapy34:72-81.","journal-title":"Chemotherapy"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.1.100"},{"key":"e_1_3_2_40_2","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1046\/j.1442-200X.2003.01679.x","volume":"45","year":"2003","unstructured":"Suzuki, K., K. Tanikawa, and T. Matsuzaki. 2003. Pharmacokinetics and dosing of arbekacin in preterm and term newborn infants. Pediatr. Int.45:175-179.","journal-title":"Pediatr. Int."},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-6576.1999.430707.x"},{"key":"e_1_3_2_42_2","first-page":"129","volume":"50","year":"1988","unstructured":"Tominaga, T., H. Kishi, T. Niijima, T. Kawamura, M. Oshi, H. Nitoh, and I. Saitoh. 1988. A study on the pharmacokinetics of HBK in patients with renal impairment. Nishinihon J. Urol.50:129-134.","journal-title":"Nishinihon J. Urol."},{"key":"e_1_3_2_43_2","first-page":"676","volume":"47","year":"1994","unstructured":"Totsuka, K., K. Shimizu, N. Mitomi, T. Niizato, and M. Araake. 1994. Evaluation of once-daily administration of arbekacin. Experimental study and determination of pharmacokinetic properties in man. Jpn. J. Antibiot.47:676-692.","journal-title":"Jpn. J. Antibiot."},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01706354"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/39.4.471"},{"key":"e_1_3_2_46_2","first-page":"104","volume":"34","year":"1986","unstructured":"Yamamoto, Y., M. Koyama, and K. Nakagawa. 1986. Phase-one clinical study on HBK. Chemotherapy34:104-116.","journal-title":"Chemotherapy"},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-199804000-00003"},{"key":"e_1_3_2_48_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.21.3.407"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00420-05","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00420-05","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T18:56:52Z","timestamp":1645469812000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.00420-05"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,11]]},"references-count":47,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2006,11]]}},"alternative-id":["10.1128\/AAC.00420-05"],"URL":"https:\/\/doi.org\/10.1128\/aac.00420-05","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,11]]},"assertion":[{"value":"2005-04-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2005-12-23","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2006-11-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}